The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.

The drug, RHB-204, is a next-generation formulation of a separate candidate from RedHill, RHB-104, which showed positive results in a Phase III trial.

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeat the disease.

Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.

Findings from the nationwide survey suggest interest in PGx while highlighting areas for UK policymakers to pay attention to, ...

The agency advises patients to confirm that any cell, gene, or tissue therapy they receive is approved by a regulator or authorized for use in a clinical trial.

NEW YORK – Aprea Therapeutics on Tuesday said it signed an agreement with MD Anderson Cancer Center to provide a supply of its WEE1 kinase inhibitor APR-1051 for a preclinical study exploring its use ...

By correcting for ancestral bias in publicly available datasets, PhyloFrame produces better outcomes predictions for under-sampled populations.

Coeptis previously held limited co-development rights to GEAR. In conjunction with the new license agreement, Coeptis has formed a majority-owned subsidiary, called GEAR Therapeutics, to evaluate GEAR ...

The Rome-based charity recently applied for marketing authorization of the same gene therapy, previously advanced by Orchard Therapeutics, in the EU.